NeoGenomics, a leader in cancer genetics testing, reported third-quarter 2021 revenue of $121 million, reflecting a 3% decrease year-over-year. Clinical Services revenue fell by 6%, though it grew 11% when excluding prior COVID-19 testing. Notably, Pharma Services revenue increased by 14% to $19 million. Operating expenses surged 76% to $88 million, impacting a net loss of $20 million. The company plans to double its sales team to enhance growth prospects for its RaDaR™ platform. Cash and equivalents totaled $546 million, while adjusted EBITDA stood at negative $3 million.

NeoGenomics, Inc. (NASDAQ:NEO) announced a leadership transition effective January 1, 2022. William Bonello, currently President of the Informatics Division, will become Chief Financial Officer, leveraging his extensive financial background to support growth initiatives. Kathryn McKenzie, the current CFO, will take on the new role of Chief Sustainability and Risk Officer, overseeing Environmental, Social, and Governance initiatives. CEO Mark Mallon expressed optimism about the appointments and their potential to drive the company's growth strategy.

NeoGenomics announced a clinical collaboration between its subsidiary Inivata and the Princess Margaret Cancer Center in Toronto to conduct two studies using liquid biopsy assays. The ACCELERATE study will compare treatment initiation times in advanced non-small cell lung cancer (NSCLC) patients using Inivata's InVisionFirst-Lung biopsy against traditional tissue profiling. The second study, ctDNA Lung, will evaluate RaDaR assay efficacy in detecting minimal residual disease after lung cancer surgery. Both studies aim to enhance treatment outcomes and accelerate patient response.

NeoGenomics, Inc. (NASDAQ:NEO) announces the release of its third quarter 2021 financial results on November 4, 2021. A webcast and conference call are scheduled for 8:30 AM EDT on the same day to discuss results. Investors can dial in or access the replay until November 18, 2021. The company specializes in cancer genetics testing and has a comprehensive testing menu for oncologists. It operates multiple accredited laboratories across the U.S., Europe, and Asia, catering to various healthcare organizations and pharmaceutical firms.

NeoGenomics, Inc. (NASDAQ:NEO) has announced a leadership transition within its Board of Directors. Lynn A. Tetrault has been appointed Non-executive Chair, succeeding Douglas M. VanOort, who will retire from the Board by year-end. Tetrault, with over 25 years in healthcare, previously served as Lead Independent Director and has extensive experience in human resources and corporate governance. This transition is expected to enhance leadership stability and direction at NeoGenomics, renowned for its cancer-focused genetic testing services.

NeoGenomics, Inc. (NASDAQ: NEO) announced its subsidiary Inivata will present significant data at the ESMO Congress from September 16-21, 2021. The focus is on the RaDaR™ assay for detecting molecular residual disease (MRD) and the InVisionFirst®-Lung liquid biopsy test. Inivata will showcase two posters on RaDaR's sensitivity in head and neck squamous cell carcinoma and early-stage breast cancer. InVisionFirst-Lung's utility in treating advanced NSCLC will also be highlighted. The data underscores the potential of these assays in enhancing cancer treatment regimens.

NeoGenomics, Inc. (NASDAQ: NEO) announced that its executive team will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 10:15 am ET. The presentation will be available via live webcast on the Company's website.

NeoGenomics specializes in cancer genetic testing and services, with laboratories across the U.S. and internationally. The company focuses on connecting patients with therapies and adheres to data protection laws to secure patient information.

NeoGenomics reported strong second-quarter 2021 results with consolidated revenue increasing by 40% to $122 million. Clinical Services revenue rose 37% to $101 million, while Pharma Services surged 55% to $20 million. The company completed two acquisitions: Trapelo Health in April and Inivata in June, enhancing its strategic position. Net income for the quarter was $76 million, reversing a $7 million loss year-over-year, although adjusted net loss was $1 million. Cash reserves totaled $373 million with an optimistic outlook for 2021.

NeoGenomics, Inc. (NASDAQ:NEO) announced its plan to release second quarter 2021 financial results on August 6, 2021. A webcast and conference call will follow at 8:30 AM EDT to discuss the results, accessible via the company's website. Investors can dial in for the conference call using the provided domestic and international numbers. NeoGenomics, a leader in cancer genetics testing, aims to connect patients with innovative therapies while adhering to data protection laws. The company operates several accredited laboratories globally.